ArticleFrontiers in pharmacology2026
A call to action for pharmacogenomics stewardship in South Africa.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacogenomics and Opioid Efficacy in Sickle Cell Disease: Is the Field Ready for Precision Prescribing?Journal of personalized medicine · 2026Review
- International expert perspectives on pharmacogenomics in pharmacy education: a qualitative study with implications for South Africa.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomics (PGx) can personalize medication therapy in South Africa's (SA) diverse populativon but faces context-specific barriers: inadequate SA-specific allele variant data, infrastructure limitations, education and training gaps, and economic constraints. This call to action proposes SA's first PGx stewardship framework to guide rational PGx testing integration. Three critical pillars are as follows (1) targeted research to build an open-access PGx variant database informed by SA data; (2) phased implementation starting with high-risk medicines in tertiary hospitals; and (3) nationally accredited PGx curricula for health professionals. All pillars are grounded in culturally responsive ethical, legal and social frameworks addressing SA's sociohistorical context. We advocate for interprofessional collaboration to position SA as a leader in equitable PGx implementation, aligning with National Health Insurance priorities to reduce adverse drug reaction (ADR) related hospitalizations by 30% within 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.